Home   >  
Angiogenesis/Protein Tyrosine Kinase

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
Sunitinib Chemical Structure
BCP02336 Sunitinib 557795-19-4
Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
OPT-302 Chemical Structure
BCP49401 OPT-302 OPT-302
OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D.
Tyrphostin AG1433 Chemical Structure
BCP48941 Tyrphostin AG1433 168835-90-3
Tyrphostin AG1433 is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1/KDR)(IC50s = 9.3 μM).
SU1498 Chemical Structure
BCP25508 SU1498 168835-82-3
SU 1498 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 (VEGFR2, aka FLK1; IC50 = 700 nM).
WAY-340935 Chemical Structure
BCP46895 WAY-340935 737818-56-3
WAY-340935 (VEGFR2-IN-2) is a potent and selective VEGFR2 inhibitor with an IC50 of 19.32 nM. VEGFR2-IN-2 can be used for researching
CEP-11981 Chemical Structure
BCP46664 CEP-11981 856691-93-5
CEP-11981 is an orally bioavailable inhibitor of vascular endothelial growth factor receptor (VEGFR) and Tie2 receptor tyrosine kinases with potential antiangiogenic and antineoplastic activities. Pan-VEGFR/Tie2 tyrosine kinase inhibitor CEP-11981 selectively binds to VEGFR and Tie2 receptor tyrosine kinases, which may result the inhibition of endothelial cell migration, proliferation and survival and the inhibition of tumor cell proliferation and tumor cell death.
Ningetinib Chemical Structure
BCP46143 Ningetinib 1394820-69-9
Ningetinib is a novel tyrosine kinase inhibitor, targeted at c-Met, Axl, VEGFR-2, Mer and Flt3.
Tivozanib hydrochloride hydrate Chemical Structure
BCP45190 Tivozanib hydrochloride hydrate 682745-41-1
Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.
XL-092 Chemical Structure
BCP40284 XL-092 2367004-54-2
XL092 is an investigational, next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in the growth and spread of cancer.
HS-1793 Chemical Structure
BCP37847 HS-1793 927885-00-5
HS-1793, inhibits hypoxia-induced HIF-1α and VEGF expression, and migration in human prostate cancer cells.
123下一页末页共 138 条记录 1 / 14 页